The maturation inhibitors are a class of antiviral drugs for the treatment of infection with HIV.
Specifically, drugs in this class disrupt the final step in the processing of the HIV-1 gag protein, the cleavage of its immediate precursor by the enzyme HIV-1 protease.
This leads to the formation of noninfectious, immature virus particles, incapable of infecting other cells.
No other class of drugs shares this mechanism of action, thus maturation inhibitors retain inhibitory activity against HIV infections with resistance.
[6] Both were developed by Myriad Genetics, which has discontinued the maturation inhibitor program in 2010.